Skye Bioscience Inc.(SKYE) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company ended 2025 with $25.7 million in cash equivalents and short-term investments, managing its operating plan to extend its runway through Q4 2026 [30] Business Line Data and Key Metrics Changes - The CBeyond program has shown a clinically meaningful 3% improvement in weight loss over semaglutide alone at 26 weeks, with a 22.3% mean weight loss in the combination arm over 52 weeks [6][18] - Participants on semaglutide alone regained 38.7% of weight over 13 weeks after stopping therapy, while those on the combination of nimacimab plus semaglutide only regained 17.8% [18] Market Data and Key Metrics Changes - The company is positioning nimacimab as a complementary therapy to GLP-1s, targeting second-line add-on settings for patients who have not achieved their weight loss goals with first-line therapies [20][21] Company Strategy and Development Direction - The company is expanding the CBeyond study to include new intravenous cohorts to rapidly generate safety and pharmacokinetic data at higher exposures [14] - The focus is on developing a co-formulation of nimacimab using Halozyme's ENHANZE technology to facilitate high-volume subcutaneous injections [16] - The company aims to determine the exposure and duration of peripheral CB1 engagement required to produce clinically meaningful efficacy [34] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of generating clinical data to support nimacimab's potential in the anti-obesity medicine landscape, particularly in combination with GLP-1s [14][19] - The feedback from the FDA has helped refine the Phase 2b protocol, particularly regarding combination therapy development [17] Other Important Information - The company is advancing its first antibody peptide conjugate program, which aims to combine nimacimab's mechanism of action with a GLP-1 receptor agonist [25][28] Q&A Session Summary Question: Plans to share data from higher dose cohorts and status of formulation work - The company is expanding into the Part C expansion study to generate data on higher exposures and expects updates by Q4 2026 [38][39] - The formulation work with Halozyme is ongoing and expected to be ready for the Phase 2b study [40][41] Question: Concerns about dose levels in the expansion study - Management believes the selected doses are sufficient for the Phase 2b selection, but they are continuing to evaluate higher dosing [48] Question: Profile and goals for the new program - The new program is seen as long-term optionality, with nimacimab remaining the core value driver [52] Question: Importance of peripheral tissues for nimacimab's clinical effect - Adipose tissue and liver are critical for nimacimab's effects, with different profiles expected for monotherapy versus combination therapy [61] Question: Use of IV in the Part C phase of the study - IV is being used for the fastest generation of high exposure PK and safety information, with plans for subcutaneous delivery in Phase IIb [65]